Sensera has acquired Nanotron Technologies
Sensera Ltd. has acquired Nanotron Technologies GmbH.
Sensera is an Internet of Things (IoT) sensor solution provider. The company designs and manufactures specialized high-performance sensors and modules in the rapidly growing global wireless sensor networks industry.
Headquartered in Germany, Nanotron Technologies is a leading provider of location awareness services. The Nanotron platform delivers a complete integrated sensor system consisting of chips, modules and software that enable precise real-time positioning and concurrent wireless communication.
Oaklins’ team in Australia acted as buy-side advisor in this transaction.
Matt Morgan
Executive Chairman, Sensera Ltd.
Contáctese con el equipo de la transacción
Transacciones relacionadas
Niscon Inc. has been acquired by SGPS ShowRig
Niscon Inc. has been successfully acquired by SGPS ShowRig, a global provider of staging, rigging and automation for live entertainment. The acquisition reinforces SGPS Showrig’s commitment to pushing the boundaries of innovation in the entertainment industry. By adding Niscon’s unique motion-control technology to its portfolio, SGPS Showrig strengthens its ability to deliver cutting-edge, precision-driven solutions.
Conozca másFairfest Media has acquired WTE Miami
Fairfest Media, organizer of OTM, the leading travel show in Asia, has acquired WTE Miami, the fastest-growing travel trade show in the USA. The acquisition marks a significant milestone in Fairfest’s global expansion, strengthening its presence in the Americas and beyond by leveraging decades of experience and leadership in Asia and India.
Conozca másBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Conozca más